BioCentury
ARTICLE | Financial News

Idera planning follow-on

February 5, 2014 2:06 AM UTC

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) proposed a follow-on late Tuesday underwritten by Piper Jaffray and Cowen. Idera's IMO-8400 is in Phase II testing to treat severe plaque psoriasis, with top-l...